Navigation Links
European Dental Biomaterial Revenues Will Grow To Over $375 Million In 2021, In Line With Rising Dental Implant Placements
Date:4/10/2013

TORONTO, April 10, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the European market for dental biomaterials will see strong expansion through 2021 as their use increases alongside dental implant procedures, which often incorporate dental biomaterials. As the European population ages and awareness of available treatments grows, dental implants will see strong adoption, driving the uptake of biomaterials.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36799LOGO )

The bone graft substitute (BGS) segment continues to generate the most revenue in the European dental biomaterial market because these products are used fairly frequently in dental implant procedures. Within the BGS market, competitors have been primarily focusing on the synthetic market in recent years because there is still room for improvement for these products.

"Despite a number of product launches in the synthetic BGS market, Geistlich is still the clear market leader with its popular Bio-Oss xenograft product," said MRG Analyst Kristina Vidug . "Geistlich has high loyalty among key opinion leaders in the dentistry industry and its product is supported by long-term, positive clinical results. Geistlich's strong position in the BGS and dental membrane markets have allowed the company to lead the dental biomaterial market overall."

In the tissue regeneration product market, Straumann continues to be the only competitor. Although BioMimetic Therapeutics' GEM 21S received CE marking early 2012, it was subsequently revoked for reevaluation at the request of Luitpold Pharmaceuticals. The product is, however, anticipated to have CE marking reinstated in the future, creating competition for Straumann.

One of the main factors hindering the European dental biomaterial market will be the high price of dental procedures. Given economic concerns in Europe, some patients are postponing or cancelling dental treatments, particularly expensive surgeries. This will be most notable in Italy and Spain, where market growth will be slow over the next few years. Sweden, on the other hand, will experience the fastest growth of the countries covered in this report because dental implant procedures are partially reimbursed.

Millennium Research Group's European Markets for Dental Biomaterials 2013 report includes procedure, unit, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for bone graft substitutes, dental membranes and tissue regeneration products in France, Germany, Italy, Spain, Sweden, Switzerland and the United Kingdom.

About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Christopher Comfort
Decision Resources Group
781-993-2597
ccomfort@dresources.com

Alex Jablokow
Millennium Research Group
617-599-8613
ajablokow@mrg.net

 


'/>"/>
SOURCE Millennium Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Western European Endoscopic Devices Market to Benefit from Increase in Minimally Invasive Surgeries, Says Frost & Sullivan
2. European Nuclear Medicine / Radiopharmaceuticals Market Worth by Reach $1.6 Billion by 2017
3. SonaCare Medical Successfully Launches New Products at European Association of Urology (EAU)
4. N30 Pharma Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society
5. Chimerixs Antiviral CMX001 Abstract Selected for an Oral Presentation at the European Group for Blood and Marrow Transplantations Annual Meeting
6. Venaxis Advances Pivotal U.S. Study and Accelerates European Market Development for APPY1 Blood-based Appendicitis Test
7. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
8. Genalyte Announces CE Mark For Maverick(TM) Detection System And Signs On First European Distributors
9. European Commission Designates MST-188 As An Orphan Medicinal Product
10. Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union
11. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... 4, 2016 Frontier Pharma: Chronic Obstructive ... Innovation Chronic Obstructive Pulmonary Disease ... inflammation of the airways and lungs. Persistent breathing ... the disease one of the leading causes of ... the world. COPD is linked to cumulative exposure ...
(Date:2/4/2016)... 2016 In response to the opioid abuse epidemic, ... for Medical Products and Tobacco, along with other FDA leaders, ... approach to opioid medications. The plan will focus on policies ... pain access to effective relief. --> ... Re-examine the risk-benefit paradigm for opioids and ensure that the ...
Breaking Medicine Technology:
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... is poised to once again host, Swirl, A Wine Tasting Event at the ...
(Date:2/5/2016)... ... February 05, 2016 , ... In ... across the country gathered at the La Valencia Hotel in San Diego, California ... Chicago was named the year’s most outstanding franchise, walking away with the coveted ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... gym use and find themselves having to wait longer to access the treadmills. It’s ... their New Year’s resolutions to lose weight and get in shape by joining gyms, ...
(Date:2/5/2016)... ... 2016 , ... Boar’s Head Brand®, one of the nation’s leading providers of ... Take the stress out of your party preparation – follow these easy, yet delicious ... of the game. , “The key to hosting a successful game-day party is creating ...
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held ... as Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, ... stated Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served ...
Breaking Medicine News(10 mins):